Novavax Files 8-K for Regulation FD Disclosure
Ticker: NVAX · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: NVAX
TL;DR
Novavax dropped an 8-K, likely with news. Watch closely.
AI Summary
On April 2, 2025, Novavax, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, indicating a potential release of material non-public information. No specific financial figures or new business developments were detailed in the provided excerpt.
Why It Matters
This filing signals Novavax may be disclosing important information, potentially impacting its stock price and investor decisions.
Risk Assessment
Risk Level: medium — Regulation FD disclosures can precede significant news, creating uncertainty and potential volatility for the stock.
Key Players & Entities
- Novavax, Inc. (company) — Registrant
- 20250402 (date) — Date of Report
- April 2, 2025 (date) — Date of earliest event reported
- Gaithersburg, Maryland (location) — Principal Executive Offices
FAQ
What specific information is Novavax disclosing under Regulation FD?
The provided excerpt does not specify the content of the Regulation FD disclosure; it only indicates that the filing is for this purpose.
When was this 8-K filing submitted?
The filing was submitted on April 2, 2025.
What is Novavax, Inc.'s principal executive office address?
Novavax, Inc.'s principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.
What is the SIC code for Novavax, Inc.?
The Standard Industrial Classification (SIC) code for Novavax, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the Commission File Number for Novavax, Inc.?
The Commission File Number for Novavax, Inc. is 000-26770.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding NOVAVAX INC (NVAX).